Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a modified vitamin a pill save sight in dry AMD?

NCT ID NCT03845582

Disease control Sponsor: Alkeus Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a daily pill called ALK-001, a modified form of vitamin A, to see if it can slow the growth of geographic atrophy—an advanced form of dry age-related macular degeneration that causes blind spots. About 300 people with the condition took either the drug or a placebo for 24 months. Researchers measured changes in the size of the atrophy and checked for side effects and vision changes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ALK-001 (a modified form of vitamin A)
What this could lead to
If successful, this could slow the progression of geographic atrophy, helping preserve vision in people with dry age-related macular degeneration.
What could go wrong
This is a mid-stage trial with only 200 participants, so results may not apply to everyone. The treatment may not slow vision loss or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

200 people

The number who actually took part.

Started

May 2019

Finished

Jun 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Major Inclusion Criteria: \- At least one eye with geographic atrophy secondary to dry age-related macular degeneration (AMD) Major Exclusion Criteria: \- Medical condition, which may interfere with the progression of GA, prevent performance of study procedures, compliance with protocol, or continuous participation in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

age-related macular degeneration dry age related macular degeneration Geographic Atrophy macular degeneration serpiginous choroiditis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age-related macular degeneration AMD Atrophy, geographic Geographic atrophy

Contacts and locations

Locations

  • Alkeus Site

    Phoenix, Arizona, 85053, United States

  • Alkeus Site

    Beverly Hills, California, 90211, United States

  • Alkeus Site

    Lakewood, Colorado, 80228, United States

  • Alkeus Site

    Clearwater, Florida, 33761, United States

  • Alkeus Site

    Fort Myers, Florida, 33912, United States

  • Alkeus Site

    Gainesville, Florida, 32601, United States

  • Alkeus Site

    Tampa, Florida, 33609, United States

  • Alkeus Site

    Winter Haven, Florida, 33880, United States

  • Alkeus Site

    Bloomington, Illinois, 61704, United States

  • Alkeus Site

    Lexington, Kentucky, 40509, United States

  • Alkeus Site

    Chevy Chase, Maryland, 20815, United States

  • Alkeus Site

    Worcester, Massachusetts, 01605, United States

  • Alkeus Site

    Grand Rapids, Michigan, 49546, United States

  • Alkeus Site

    Edina, Minnesota, 55435, United States

  • Alkeus Site

    Northfield, New Jersey, 08225, United States

  • Alkeus Site

    Great Neck, New York, 11021, United States

  • Alkeus Site

    Hauppauge, New York, 11788, United States

  • Alkeus Site

    Cleveland, Ohio, 44122, United States

  • Alkeus Site

    Ashland, Oregon, 97520, United States

  • Alkeus Site

    Houston, Texas, 77025, United States

  • Alkeus Site

    Fairfax, Virginia, 22031, United States

  • Alkeus Site

    Silverdale, Washington, 98383, United States

  • Alkeus Site-1

    San Antonio, Texas, 78240, United States

  • Alkeus Site-2

    San Antonio, Texas, 78240, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.